G:
LIVE

Serial Number

98113046

Owner

Generate Biomedicines, Inc.

Attorney

Jennifer M. Mikulina

Filing Date

Aug 2, 2023

Add to watchlist:

No watchlists yet
View on USPTO

G: Trademark

Serial Number: 98113046

G: is a trademark filed by Generate Biomedicines, Inc. on August 2, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Generate Biomedicines, Inc.

101 South Street, Suite 900
Somerville, MA 02143

Entity Type: 03

Trademark Details

Filing Date

August 2, 2023

Registration Date

Not Registered

Published for Opposition

August 13, 2024

Goods & Services

Pharmaceutical therapeutic preparations, pharmaceutical preparations, medical therapeutics in the nature of pharmaceutical preparations, therapeutic vaccines, and prophylactic vaccines, and medical pharmaceutical preparations in the fields of oncology, infectious disease, virology, cardiology, allergy, immunology, rheumatology, endocrinology, pulmonology, gastroenterology, and dermatology for treating infectious diseases, cancer, asthma, chronic obstructive pulmonary disease, atopic dermatitis, chronic rhinosinusitis with nasal polyps, inflammatory bowel disease, allergic disease, inflammatory disease, respiratory inflammation or fibrosis, cardiovascular diseases, gout, obesity, neurological conditions, and Sjögren's syndrome, all of the aforesaid developed using artificial intelligence technology

Downloadable computer software for use in the pharmaceuticals and healthcare fields, namely, for molecular research, research and development of pharmaceutical products and chemical compounds, design of chemical structures, and analysis of biological or chemical activity; downloadable artificial intelligence software for use in the pharmaceuticals and healthcare fields for molecular research, research and development of pharmaceutical products and chemical compounds, design of chemical structures, and analysis of biological or chemical activity in connection with pharmaceutical drug discovery and development; downloadable artificial intelligence software for use in the field of healthcare for molecular research, research and development of pharmaceutical products and chemical compounds, design of chemical structures, and analysis of biological or chemical activity

Research, development, and design of pharmaceuticals and medicines for others; scientific research in the field of pharmaceutical and medicine design, discovery and development services for others; research and development of technology for others in the field of pharmaceuticals; research and development of technology for others in the field of computational biology; pharmaceutical, medical, scientific, biotechnology, and biopharmaceutical research and development for others; collecting and analyzing complex biological data through the use of artificial intelligence, namely, data automation and collection service using proprietary software to evaluate, analyze and collect biological data; computer assisted molecule design involving the use of artificial intelligence technology, namely, product design and development in the field of medicine; conducting scientific and pharmaceutical artificial intelligence research services for others to identify molecules and compounds for drug development, namely, scientific research in the field of pharmaceuticals; providing online non-downloadable computer software for use in the pharmaceuticals and healthcare fields, namely, for molecular research, research and development of pharmaceutical products and chemical compounds, cell analysis, design of chemical structures, and analysis of biological or chemical activity; providing online non-downloadable artificial intelligence software for use in the pharmaceuticals and healthcare fields, namely, for diagnostic and therapeutic use, and for data mining in connection with pharmaceutical drug discovery, drug development, pharmaceutical market access, chemogenomics, toxicogenomics and drug response prediction; providing online non-downloadable self-learning and artificial intelligence software for use in the field of healthcare for molecular research, research and development of pharmaceutical products and chemical compounds, cell analysis, design of chemical structures, and analysis of biological or chemical activity; providing online non-downloadable software using artificial intelligence for use in the biotechnology field for discovering and designing biomolecules

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 7, 2026 EXRA
SOU EXTENSION 2 GRANTED
Mar 6, 2026 EX2G
SOU EXTENSION 2 FILED
Mar 6, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 6, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 15, 2025 EXRA
SOU EXTENSION 1 GRANTED
Sep 8, 2025 EX1G
SOU EXTENSION 1 FILED
Sep 8, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 8, 2025 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 3, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 3, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 3, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 3, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 3, 2025 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 1, 2025 NOAM
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Feb 20, 2025 ETOP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 3, 2025 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 3, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 3, 2025 COAR
EXTENSION OF TIME TO OPPOSE RECEIVED
Sep 10, 2024 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 13, 2024 NPUB
PUBLISHED FOR OPPOSITION
Aug 13, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 24, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 5, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 3, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 3, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 3, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 10, 2024 GNRN
NON-FINAL ACTION E-MAILED
Apr 10, 2024 GNRT
NON-FINAL ACTION WRITTEN
Apr 10, 2024 CNRT
ASSIGNED TO EXAMINER
Apr 3, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 31, 2023 NWOS
NEW APPLICATION ENTERED
Aug 5, 2023 NWAP